Mandate

Vinge advises Axcel VI and Currentum in connection with the acquisition of the Ipart Group

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of the Ipart Group which includes the companies SP-gruppen AB, Klimatentreprenad Värmland AB, Rörinstallationer i Karlstad AB, Ulvsby Rör AB, MeR El AB, and GÖREL Norden AB.

The companies provide services within ventilation, heating and sanitation, electricity and safety and are based in the western and central parts of Sweden. The Ipart Group has a turnover of approximately SEK 350 million and approximately 100 employees. Following the acquisition, Currentum is expected to have a turnover of approximately SEK 2.5 billion and will engage just over 900 employees. The transaction is subject to customary regulatory approvals.

Vinge’s team consisted of partner Christina Kokko together with Karl Klackenberg, Hannah Kajlinger, and Linnea Petersson (M&A), Isak Willborg (Construction), Elin Broman (Employment), Michaela Ådén (Financing), Ulf Pyk (Real Estate) and Julia Hagelberg (Project and VDR Assistant).

Related

Vinge advises Atria Sverige in conjunction with an investment in Cookin Food

Atria Sverige has acquired a 25 per cent stake in the Swedish convenience food company Cookin Food Sweden AB. The transaction has been performed through the acquisition of shares in Bite Delight AB, which owns Cookin Food Sweden AB. Atria holds an option to acquire the remaining shares in Bite Delight AB after 2028.
March 04, 2026

Vinge advises Revivo Group on the acquisition of Solidenergy

Revivo Group, a portfolio company of Helix Kapital, has acquired Solidenergy, a leading provider of surface treatment services in the Norwegian market. The company operates within the energy, offshore and infrastructure sectors and is headquartered in Ågotnes outside Bergen. Solidenergy employs approximately 600 people.
March 03, 2026

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a partially guaranteed rights issue which is expected to provide Oncopeptides with proceeds of approximately SEK 200 million before deduction of transaction costs.
March 03, 2026